CN1408353A - Use of tanshin polyphenolic acid B in preparing tumor curing medicine - Google Patents
Use of tanshin polyphenolic acid B in preparing tumor curing medicine Download PDFInfo
- Publication number
- CN1408353A CN1408353A CN 02136970 CN02136970A CN1408353A CN 1408353 A CN1408353 A CN 1408353A CN 02136970 CN02136970 CN 02136970 CN 02136970 A CN02136970 A CN 02136970A CN 1408353 A CN1408353 A CN 1408353A
- Authority
- CN
- China
- Prior art keywords
- salvianolic acid
- ion
- medicine
- polyphenolic acid
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a new application of tanshin polyphenolic acid B in preparing medicine for treating tumor. Extraneous research shows that tanshin polyphenolic acid B has the function of killing tumor cell and animal test shows its antineoplastic effect. In the present invention, the cation in the salt of tanshin polyphenolic acid B may be Fe ion, Na ion, K ion, Ca ion or Mg ion, preferably Mg ion. The said medicine may be in any medicine form, oral liquid, injection, tablet or capsule.
Description
Technical field:
The present invention relates to field of medicaments, relate in particular to the application of salvianolic acid B, the particularly salvianolic acid B application in preparation medicine for treating tumor thing.
Background technology:
Operation, chemotherapy and radiotherapy are three great tradition therapies of treatment malignant tumor.Yet relapse rate is but high always behind the malignant tumor operation, and chemotherapy and radiotherapy not only bring the side effect of destruction property to the patient, and often owing to problems such as chemical sproof generation and sensitivity are not strong make curative effect limited.
Radix Salviae Miltiorrhizae is the Chinese medicine of China, has the effect of blood circulation promoting and blood stasis dispelling, dredge the meridian passage.Salvianolic acid B is one of aqueous soluble active constituent of Radix Salviae Miltiorrhizae, and its chemical constitution is as follows:
Wherein, F is a metal cation; discovering these years; water-soluble components is important active ingredient in the Radix Salviae Miltiorrhizae; because salvianolic acid is difficult to obtain pure product; and danshensu and protocatechualdehyde are more easily separated and synthetic; so most of pharmaceutical factories are danshensu and the protocatechualdehyde quality control index as Danshen root injection; also there is part pharmaceutical factory that salvianolic acid B salt is used to prevent cardiovascular and cerebrovascular disease, prevention alzheimer disease; treatment renal failure is improved in the medicines such as uremic symptom, antioxidation, antithrombotic, anti-cardiac-cerebral ischemia, the liver protecting and blood lipid regulation.
Summary of the invention:
Technical problem to be solved by this invention is: because in the prior art; most of pharmaceutical factories are danshensu and the protocatechualdehyde quality control index as Danshen root injection; also have salvianolic acid B salt is used to prevent cardiovascular and cerebrovascular disease, prevention alzheimer disease; treatment renal failure is improved in the medicines such as uremic symptom, antioxidation, antithrombotic, anti-cardiac-cerebral ischemia, the liver protecting and blood lipid regulation.But do not meet the application in the medicine of using it for preparation treatment tumor.The present invention is for solving the above-mentioned technical problem in the prior art, and the technical scheme that is adopted provides the new purposes of salvianolic acid B, i.e. the application of salvianolic acid B in preparation medicine for treating tumor thing.At the salt apoplexy due to endogenous wind of salvianolic acid B of the present invention, its cation can be iron ion, sodium ion, potassium ion, calcium ion or magnesium ion, preferably magnesium ion.The dosage form of the medicine of preparation of the present invention treatment tumor can be oral liquid type, injection type, tablet form or capsule-type for the above dosage form of any pharmaceutics.In vitro study shows that salvianolic acid B has lethal effect to tumor cell, experimental results show that in the animal body that it has antitumor curative effect.
Description of drawings:
Fig. 1 suppresses the dose-effect relationship figure of growth of tumour cell for salvianolic acid B.
Wherein, abscissa is represented the concentration of salvianolic acid B solution, and unit is umol/L; Vertical coordinate is represented
Absorbance (A).1 is the SK-Hep1 cell strain, and 2 is the Huh-7 cell strain, and 3 is SMMU-7721
Cell strain, 4 is the H22 cell strain, 5 is the Hela cell strain.
Fig. 2 is the influence of salvianolic acid B to the transplanted hepatoma mice time-to-live.
Wherein, abscissa express time (natural law), vertical coordinate is represented the number of elements of survival mice,
■ is not administration group, ▲ be the administration group.
Fig. 3 lures the therapeutical effect figure of cancer rat liver cancer for salvianolic acid B to chemistry.
Wherein, ■ is a tumor group, treatment group,
Be normal group.
The specific embodiment:
The extracting method of Radix Salviae Miltiorrhizae
Radix Salviae Miltiorrhizae (Salvia miltionrrhiza Bge.) is ground into 100 order powder after removing impurity such as silt, and water heating extraction three times merges aqueous extract, and concentrating under reduced pressure, concentrated solution add alcohol (methanol, ethanol) and contain the alcohol amount to 70-80%, put cold spending the night; Remove precipitation with centrifuge, solution is removed alcohol, crosses macroporous resin (model Diaion HP20 or 400-1 type), water, ethanol elution, collect the phenolic acid part, be concentrated into small size, again by gel column (MCI gel, TSK HF40w, SephadexLH-20, Silica gel ODSG3 etc.), water one ethanol elution is collected the eluent that contains the salvianolic acid B part.With the eluent rotary evaporation in vacuo, remove ethanol, lyophilization obtains salvianolic acid B dry powder.
Salvianolic acid B suppresses the dose-effect relationship figure of growth of tumour cell
Select human hepatoma cell strain SK-Hepl, Huh7, SMMU-7721, rat liver cancer cell strain H22, human cervical carcinoma cell strain Hela experimentize (except that the Hela cell strain available from Shanghai RESEARCH ON CELL-BIOLOGY institute of the Chinese Academy of Sciences cell bank, above cell strain is all by the present of auspicious moral hepatic disease institute).Cultivate above-mentioned cell respectively with the RPMI-1640 that contains 10% calf serum (available from Sigma) culture fluid,, prepare cell suspension, and cell concentration is transferred to 1 * 10 with 0.25% pancreatin (available from Sigma) digestion cell monolayer
5/ ml.Get 96 well culture plates, every hole adds 100ul cell suspension, and overnight incubation makes cell attachment.0.27,2.7,27,270umol/L culture fluid is removed in suction, adds the culture fluid contain salvianolic acid B, and the salvianolic acid B final concentration is respectively:, observe its effect to tumor cell with tetrazolium (MTT) (available from Sigma) reducing process after 48 hours.Fig. 1 shows that the salvianolic acid B of each concentration all has inhibitory action to tumor cell, and has dose-effect relationship.
Salvianolic acid B is to the effect of animal inoculation tumor treatment
Get 20 C57 mices (male and female dual-purpose, body weight 18-22g is available from the Shanghai Experimental Animal Center), all subcutaneous vaccination concentration of every mice is 1 * 10
7The Hep1-6 hepatoma carcinoma cell of/ml; Grow the tumor that diameter is 1-2cm after 16 days in the mice body.Be divided into two group with mice this moment, i.e. matched group and treatment group, 10 every group.From the 17th day treatment group mouse peritoneal injection salvianolic acid B solution, once a day, dosage was 100mg/kg (concentration of salvianolic acid B solution is 5mg/ml, prepares with normal saline); Control group mice lumbar injection every day isometric(al) normal saline once in contrast.As shown in Figure 2, the result shows that the life span of treatment group mice prolongs.
Red acetic acid B is to the effect of zoochemistry inductivity tumor treatment
36 Wistar rats (male and female dual-purpose, body weight 180-220g is available from the Shanghai Experimental Animal Center) are divided into three groups, i.e. normal control group, model control group and salvianolic acid B treatment group, 12 every group.Before the formal experiment beginning, give model control group earlier and salvianolic acid B treatment group rat was drunk 0.01% diethylnitrosamine solution 3 months, bring out the purpose that produces tumor in the body to reach; And normal rats still gives normal diet during this period.After the modeling success, each group rat is handled: 1. normal control group: intraperitoneal injection of saline: 2. tumor matched group: intraperitoneal injection of saline according to following method; 3, salvianolic acid B treatment group: lumbar injection concentration is the salvianolic acid B solution of 5mg/ml, and once a day, dosage is 50mg/kg (salvianolic acid B solution adopts the normal saline preparation).Treat after 30 days blood is got in each group rat execution, detect serum albumin (albumin in the blood, ALB), glutamate pyruvate transaminase (alanine aminotransferase, ALT), γ one glutamyl transpeptidase (γ-glutamyltransferase, γ-GT), alkali phosphatase (alkaline phosphatase, content ALP).As shown in Figure 3, the result shows that the laboratory indexes of salvianolic acid B treatment group is clearly better than the tumor matched group.
Claims (5)
1, the application of salvianolic acid B in preparation medicine for treating tumor thing.
2, the application of salvianolic acid B as claimed in claim 1 in preparation medicine for treating tumor thing, it is characterized in that: the salt apoplexy due to endogenous wind of described salvianolic acid B, its cation are iron ion, sodium ion, potassium ion calcium ion or magnesium ion.
3, the application of salvianolic acid B as claimed in claim 1 or 2 in preparation medicine for treating tumor thing, it is characterized in that: the salt apoplexy due to endogenous wind of described salvianolic acid B, its cation are magnesium ion.
4, the application of salvianolic acid B as claimed in claim 1 in preparation medicine for treating tumor thing is characterized in that: the dosage form of the medicine of described preparation treatment tumor is the above a dosage form of any pharmaceutics.
5, the application of salvianolic acid B as claimed in claim 1 in preparation medicine for treating tumor thing is characterized in that: the dosage form of the medicine of described preparation treatment tumor is oral liquid type, injection type, tablet form or capsule-type.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02136970 CN1408353A (en) | 2002-09-13 | 2002-09-13 | Use of tanshin polyphenolic acid B in preparing tumor curing medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02136970 CN1408353A (en) | 2002-09-13 | 2002-09-13 | Use of tanshin polyphenolic acid B in preparing tumor curing medicine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101395197A Division CN101664400B (en) | 2002-09-13 | 2002-09-13 | Application of salvianolic acid B to preparation of medicament for treating tumor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1408353A true CN1408353A (en) | 2003-04-09 |
Family
ID=4748835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02136970 Pending CN1408353A (en) | 2002-09-13 | 2002-09-13 | Use of tanshin polyphenolic acid B in preparing tumor curing medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1408353A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100341581C (en) * | 2005-07-29 | 2007-10-10 | 上海第二医科大学附属第九人民医院 | Method of thalidomide for effective interventing oral cancer in animal model |
| CN102218140A (en) * | 2010-04-15 | 2011-10-19 | 上海天甲生物医药有限公司 | Tumor resistance effect of medicine combination of salvianolic acid B and coxib medicaments |
| CN101367799B (en) * | 2008-10-06 | 2011-11-30 | 李国玉 | Matrine salviol acid B complex salt and kuh-seng native salviol acid B complex salt, preparation method and application thereof |
| CN105434436A (en) * | 2015-12-25 | 2016-03-30 | 于非 | Medical application of salvianolic acid B sophocarpidine salt in protecting from inflammations caused by TNF-alpha or IL6 |
-
2002
- 2002-09-13 CN CN 02136970 patent/CN1408353A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100341581C (en) * | 2005-07-29 | 2007-10-10 | 上海第二医科大学附属第九人民医院 | Method of thalidomide for effective interventing oral cancer in animal model |
| CN101367799B (en) * | 2008-10-06 | 2011-11-30 | 李国玉 | Matrine salviol acid B complex salt and kuh-seng native salviol acid B complex salt, preparation method and application thereof |
| CN102218140A (en) * | 2010-04-15 | 2011-10-19 | 上海天甲生物医药有限公司 | Tumor resistance effect of medicine combination of salvianolic acid B and coxib medicaments |
| CN102218140B (en) * | 2010-04-15 | 2013-03-27 | 上海天甲生物医药有限公司 | Tumor resistance effect of medicine combination of salvianolic acid B and coxib medicaments |
| CN105434436A (en) * | 2015-12-25 | 2016-03-30 | 于非 | Medical application of salvianolic acid B sophocarpidine salt in protecting from inflammations caused by TNF-alpha or IL6 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103768534B (en) | A kind of Chinese medicine composition with antitumor activity | |
| CN105902604B (en) | Compound medicine for treating acute T lymphocyte leukemia | |
| CN101904974B (en) | Chinese medicinal composition for treating malignant tumor diseases and preparation method thereof | |
| CN101664400B (en) | Application of salvianolic acid B to preparation of medicament for treating tumor | |
| CN101537036A (en) | Soap pod saponin extract as well as preparation method and application thereof | |
| CN1408353A (en) | Use of tanshin polyphenolic acid B in preparing tumor curing medicine | |
| CN1775267A (en) | Kaikoujian extract, Its preparing method and use | |
| WO2018188546A1 (en) | New use of isaria cicadae miquel | |
| CN101890152B (en) | Application of Chinese yam glycoprotein in preparation of antihypoxic and antifatigue medicaments | |
| CN101564466A (en) | Traditional Chinese medicine effective part composition containing antineoplastic active ingredients as well as preparation method and application thereof | |
| WO2022206250A1 (en) | Use of alkaloid compound in preparation of product for preventing and/or treating cardiac injury | |
| CN102552512A (en) | Traditional Chinese medicine used for treating hepatitis B | |
| CN107266599B (en) | Flammulina velutipes, extracting method and its application in terms of functional consitipation drug is treated in preparation | |
| CN112691135B (en) | Anti-tumor traditional Chinese medicine composition and application thereof | |
| WO2017202113A1 (en) | Use of rosmarinic acid-4-o-β-d-glucoside in preparing drug for preventing and treating influenza | |
| CN100406026C (en) | Medicine for treating chronic gastritis and gastric carcinoma, and its prepn. method | |
| CN106063794A (en) | Phillyrin, its derivant, phillyrin and phillygenol compositions in preparation prevention or/and application in treatment liver injury medicament | |
| CN102499933B (en) | Application of cerebroside B compound | |
| CN101632829B (en) | Anti-hepatofibrosis traditional Chinese medicament composition, preparation method thereof and medicament preparation | |
| CN1709225A (en) | Method for preparing health-care foods for auxiliary inhibiting tumour using polygonum cuspidatum extract | |
| CN100421689C (en) | Preparation technology of crataegus total phenolic acid portion and application | |
| CN100411663C (en) | Anticancer compound Chinese medicine powder and its preparing method | |
| CN100478009C (en) | Chinese medicine for anti-tumor and its preparing method | |
| WO2018188547A1 (en) | New use of cordyceps sobolifera | |
| CN105477068B (en) | Preparation method and application of active site of mulberry branch and leaf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: TIANJIA BIOLOGICAL MEIDICNE CO., LTD., SHANGHAI; Free format text: FORMER OWNER: TIANJIA BIOLOGICAL MEIDICNE CO., LTD., SHANGHAI Effective date: 20060630 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20060630 Address after: 200003 West 5G, 318 North Chongqing Road, Shanghai, Huangpu District Applicant after: Tianjia Biological Meidicne Co., Ltd., Shanghai Co-applicant after: Dongfang Tianjia Tech Development Co., Ltd. Beijing Address before: 200003 West 5G, 318 North Chongqing Road, Shanghai, Huangpu District Applicant before: Tianjia Biological Meidicne Co., Ltd., Shanghai |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |